Investigational New Drugs

, Volume 30, Issue 2, pp 723–728 | Cite as

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

  • Robert J. MorganJr
  • Lucille Leong
  • Warren Chow
  • David Gandara
  • Paul Frankel
  • Agustin Garcia
  • Heinz-Josef Lenz
  • James H. Doroshow
PHASE II STUDIES

Summary

Background The California Cancer Consortium has performed a Phase II trial of infusional bryostatin, a protein kinase C inhibitor isolated from the marine invertebrate bryozoan, Bugula Neritina, a member of the phylum Ectoprocta, in combination with cisplatin, in patients (pts) with recurrent platinum-sensitive or resistant ovarian cancer (OC). Methods Pts received bryostatin 45 mcg/m2 as a 72 h continuous infusion followed by cisplatin 50 mg/m2. Cycles were repeated every 3 weeks. Dosages were chosen based on phase I data obtained by the CCC in a population of pts with mixed tumor types. Results Eight pts with recurrent or persistent epithelial OC received 23 cycles of treatment. All pts had received previous platinum-based chemotherapy; two pts had received one prior course, five had received two prior courses, and one had received three prior courses of chemotherapy. The median age was 64 (range 32–72), and Karnofsky performance status 90 (range 80–100). A median of 3 cycles of chemotherapy were delivered (range: 1–5). The median progression-free and overall survivals were 3 and 8.2 months respectively. Best responses included two partial responses (one in a platinum-resistant pt), three pts with stable disease, and three progressions. All pts experienced Grade 3 or 4 toxicities including severe myalgias/pain/fatigue/asthenia in six pts, and severe nausea/vomiting/constipation in two other pts. One pt experienced a seizure and liver function tests were elevated in one other. Conclusions A modest response rate is observed in pts with recurrent or persistent ovarian cancer treated with the combination of bryostatin and cisplatin. The toxicity profile, however, observed in this pt population (primarily severe myalgias), precludes tolerability and prevents this combination from further investigation at this dose and schedule. It is possible that platinum pre-exposure in OC patients exacerbates observed toxicity. Phase II dosages of investigational agents in OC pts that are determined by phase I trials in pts with other tumor types should be chosen cautiously.

Keywords

Chemomodulation Chemotherapy Phase II Bryostatin Cisplatin 

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249PubMedCrossRefGoogle Scholar
  2. 2.
    Cannistra SA, Gershenson D, Recht A (2008) Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT Jr, Lawrence TS, Rosenberg S (eds) Cancer: principles and practice of oncology. Lippincott Williams & Wilkins, Philadelphia, pp 1568–1594Google Scholar
  3. 3.
    Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(26):1950–1955PubMedCrossRefGoogle Scholar
  4. 4.
    Sabbatini P, Spriggs D (1998) Salvage therapy for ovarian cancer. Oncology 12(6):833–848PubMedGoogle Scholar
  5. 5.
    Stanwell C, Gescher A, Bradshaw TD, Pettit GR (1994) The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int J Cancer 56:585–592PubMedCrossRefGoogle Scholar
  6. 6.
    Hornung RL, Pearson JW, Beckwith M, Longo DL (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52:101–107PubMedGoogle Scholar
  7. 7.
    Dale IL, Bradshaw TD, Gescher A, Pettit GR (1989) Comparison of effects of bryostatins 1 and 2 and 12-O- tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. Cancer Res 49:3242–3245PubMedGoogle Scholar
  8. 8.
    Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR, Grant S (1994) Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47:839–852PubMedGoogle Scholar
  9. 9.
    Asiedu C, Biggs J, Lilly M, Kraft AS (1995) Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin- dependent kinase 2. Cancer Res 55:3716–3720PubMedGoogle Scholar
  10. 10.
    Basu A, Lazo JS (1992) Sensitization of human cervical carcinoma cells to cis- diamminedichloroplatinum(II) by bryostatin 1. Cancer Res 52:3119–3124PubMedGoogle Scholar
  11. 11.
    Hofmann J, Doppler W, Jakob A, Maly K, Posch L, Uberall F, Grunicke HH (1988) Enhancement of the antiproliferative effect of cis- diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42:382–388PubMedCrossRefGoogle Scholar
  12. 12.
    Isonishi S, Andrews PA, Howell SB (1990) Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O- tetradecanoylphorbol 13-acetate. J Biol Chem 265:3623–3627PubMedGoogle Scholar
  13. 13.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRefGoogle Scholar
  14. 14.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  15. 15.
    Green S, Weiss G (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239–253PubMedCrossRefGoogle Scholar
  16. 16.
    Stanwell C (1994) The role of protein kinase C (PKC) modulation in the antiproliferative effects of bistratene A, bryostatin 1 and phorbol esters. Diss Abstr Int [C] 55:881Google Scholar
  17. 17.
    Dale IL, Gescher A (1989) Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer 43:158–163PubMedCrossRefGoogle Scholar
  18. 18.
    Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD (1991) Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51:682–687PubMedGoogle Scholar
  19. 19.
    Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-Katib AM (1998) Phase I study of bryostatin 1 in patients with relapsed non- Hodgkin’s lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16:56–62PubMedGoogle Scholar
  20. 20.
    Basu A, Teicher BA, Lazo JS (1990) Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem 265:8451–8457PubMedGoogle Scholar
  21. 21.
    Martiny-Baron G, Fabbro D (2007) Classical PKC isoforms in cancer. Pharmacol Res 55:477–486PubMedCrossRefGoogle Scholar
  22. 22.
    Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E (2006) Preclinical and clinical development of novel agents that target the protein kinase C Family. Sem Oncol 33:466–478CrossRefGoogle Scholar
  23. 23.
    Hanauske A-R, Sundell K, Lahn M (2004) The role of protein kinases C-alpha (PKC-α) in cancer and its modulation by the novel PKC-α-specific inhibitor aprinocarsen. Curr Pharm Des 10(16):1923–1936PubMedCrossRefGoogle Scholar
  24. 24.
    Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F (2009) Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemother Pharmacol 64:803–810PubMedCrossRefGoogle Scholar
  25. 25.
    Hickman PF, Kemp GJ, Thompson CH, Salisbury AJ, Wade K, Harris AL, Radda GK (1995) Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br J Cancer 72:998–1003PubMedCrossRefGoogle Scholar
  26. 26.
    Thompson CH, Macaulay VM, O’Byrne KJ, Kemp GJ, Wilner SM, Talbot DC, Harris AL, Radda GK (1996) Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br J Cancer 73:1161–1165PubMedCrossRefGoogle Scholar
  27. 27.
    Lenz HJ, Raghavan D, Doroshow J, Gandara DR (1999) Phase I study of bryostatin-1 in combination with cisplatin in treating patients with metastatic or unresectable solid tumors including non small-cell lung cancer. Clin Lung Cancer 1(2):151–152PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Robert J. MorganJr
    • 1
  • Lucille Leong
    • 1
  • Warren Chow
    • 1
  • David Gandara
    • 2
  • Paul Frankel
    • 3
  • Agustin Garcia
    • 4
  • Heinz-Josef Lenz
    • 4
  • James H. Doroshow
    • 1
    • 5
  1. 1.Department of Medical Oncology and Therapeutics ResearchCity of Hope National Medical CenterDuarteUSA
  2. 2.University of California, DavisDavisUSA
  3. 3.Department of BiostatisticsCity of Hope National Medical CenterDuarteUSA
  4. 4.University of Southern CaliforniaLos AngelesUSA
  5. 5.Division of Cancer Treatment and DiagnosisNational Cancer InstituteBethesdaUSA

Personalised recommendations